课题基金 / 基金详情

Therapeutics Core (Page 286)

Therapeutics Core (Page 286)
治疗核心(第286页)
批准号:
8629789
负责人:
Howard E Gendelman
金额:
$17.69万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Howard E Gendelman的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (See instructions): The goals of the Therapeutics core are to provide nanoformulations to invesfigators pursuing nanoformulated ntiretroviral and neuroprotective therapies for increased central nervous system (CNS) penetrance. The formulations developed address how monocytes and other immune cells may be harnessed for drug delivery. Before such novel therapies can be administered to people, we will determine, in well-validated laboratory and animal models, the optimal doses and formulation administration. The crux of the problem facing the Core, namely can nanoformulated antiretroviral therapy show sustained antiretroviral responses and slow release of drug in tissues, has now been addressed. The Core addresses a specific and important issue in the treatment of HIV and neuroAIDS, with broader implications for therapeutic interventions to other neurodegenerative diseases. Through this project, we will identify and manufacture candidate Nanoformulations of currently used efficacious antiretrovirals. These will be tested model systems of human disease, ranging from cultured monocytes to mice to monkeys, to examine pharmacokinefic, safety and efficacy. This Core, overall, represents work that may prove to be a major advance in the development of long-lasting therapeutic agents that can lead to real treatments both systemic and CNS human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV-1DetectionandEliminationFrom CNS Mononuclear Phagocytes
HIV-1DetectionandEliminationFrom CNS Mononuclear Phagocytes
HIV-1 Detection and Elimination From CNS Mononuclear Phagocytes
Neuroimmunology of Disease Training Program